Onco-Innovations Successfully Scales Up Key Materials for PNKP Inhibitor Program

Onco-Innovations Limited announced the successful scale-up of crucial intermediates, A83 and B4. This marks a significant progress in the company's manufacturing efforts supporting ONC010, its lead PNKP inhibitor drug candidate.

The collaboration with Dalton Pharma Services advanced the production of these intermediates from laboratory to intermediate scale. This achievement reinforces the scalability and reliability of the manufacturing pathway for ONC010, crucial for ongoing preclinical studies and future clinical trials.

CEO Thomas O'Shaughnessy highlighted this as a pivotal step in reducing manufacturing risks, fortifying Onco's CMC program. The partnership with Dalton showcases their capability in complex drug development.

Ongoing efforts include integrated synthesis, analytical development, and polymer platform scale-up, aligning with preclinical and clinical development plans.